{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:44:24Z","timestamp":1776872664301,"version":"3.51.2"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MEC-URO\/ 29043\/2017"],"award-info":[{"award-number":["PTDC\/MEC-URO\/ 29043\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/132751\/2017"],"award-info":[{"award-number":["SFRH\/BD\/132751\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["DFA\/BD\/6038\/2020"],"award-info":[{"award-number":["DFA\/BD\/6038\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/136007\/2018"],"award-info":[{"award-number":["SFRH\/BD\/136007\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Germ cell tumors (GCTs) are developmental cancers, tightly linked to embryogenesis and germ cell development. The recent and expanding field of RNA modifications is being increasingly implicated in such molecular events, as well as in tumor progression and resistance to therapy, but still rarely explored in GCTs. In this work, and as a follow-up of our recent study on this topic in TGCT tissue samples, we aim to investigate the role of N6-methyladenosine (m<jats:sup>6<\/jats:sup>A), the most abundant of such modifications in mRNA, in in vitro and in vivo models representative of such tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four cell lines representative of GCTs (three testicular and one mediastinal), including an isogenic cisplatin resistant subline, were used. CRISPR\/Cas9-mediated knockdown of VIRMA was established and the chorioallantoic membrane assay was used to study its phenotypic effect in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We demonstrated the differential expression of the various m<jats:sup>6<\/jats:sup>A writers, readers and erasers in GCT cell lines representative of the major classes of these tumors, seminomas and non-seminomas, and we evidenced changes occurring upon differentiation with all-trans retinoic acid treatment. We showed differential expression also among cells sensitive and resistant to cisplatin treatment, implicating these players in acquisition of cisplatin resistant phenotype. Knockdown of VIRMA led to disruption of the remaining methyltransferase complex and decrease in m<jats:sup>6<\/jats:sup>A abundance, as well as overall reduced tumor aggressiveness (with decreased cell viability, tumor cell proliferation, migration, and invasion) and increased sensitivity to cisplatin treatment, both in vitro and confirmed in vivo. Enhanced response to cisplatin after VIRMA knockdown was related to significant increase in DNA damage (with higher \u03b3H2AX and GADD45B levels) and downregulation of XLF and MRE11.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>VIRMA has an oncogenic role in GCTs confirming our previous tissue-based study and is further involved in response to cisplatin by interfering with DNA repair. These data contribute to our better understanding of the emergence of cisplatin resistance in GCTs and support recent attempts to therapeutically target elements of the m<jats:sup>6<\/jats:sup>A writer complex.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-021-02072-9","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T08:02:54Z","timestamp":1629964974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors"],"prefix":"10.1186","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4231-5532","authenticated-orcid":false,"given":"Vera","family":"Miranda-Gon\u00e7alves","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-1391","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Lobo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-3872","authenticated-orcid":false,"given":"Catarina","family":"Guimar\u00e3es-Teixeira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6746-6807","authenticated-orcid":false,"given":"Daniela","family":"Barros-Silva","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Guimar\u00e3es","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Cantante","sequence":"additional","affiliation":[]},{"given":"Isaac","family":"Braga","sequence":"additional","affiliation":[]},{"given":"Joaquina","family":"Maur\u00edcio","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-3418","authenticated-orcid":false,"given":"Christoph","family":"Oing","sequence":"additional","affiliation":[]},{"given":"Friedemann","family":"Honecker","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4483-845X","authenticated-orcid":false,"given":"Daniel","family":"Nettersheim","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8146-1911","authenticated-orcid":false,"given":"Leendert H. J.","family":"Looijenga","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"issue":"1","key":"2072_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13059-018-1394-4","volume":"19","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Park E, Lin L, Xing Y. A panoramic view of RNA modifications: exploring new frontiers. Genome Biol. 2018;19(1):11. https:\/\/doi.org\/10.1186\/s13059-018-1394-4.","journal-title":"Genome Biol"},{"issue":"D1","key":"2072_CR2","doi-asserted-by":"publisher","first-page":"D303","DOI":"10.1093\/nar\/gkx1030","volume":"46","author":"P Boccaletto","year":"2018","unstructured":"Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wirecki TK, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46(D1):D303\u2013D7. https:\/\/doi.org\/10.1093\/nar\/gkx1030.","journal-title":"Nucleic Acids Res"},{"key":"2072_CR3","doi-asserted-by":"crossref","unstructured":"Lobo J, Barros-Silva D, Henrique R, Jeronimo C. The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors. Genes (Basel). 2018;9(11):552.","DOI":"10.3390\/genes9110552"},{"issue":"10","key":"2072_CR4","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1111\/jcmm.13804","volume":"22","author":"L He","year":"2018","unstructured":"He L, Li J, Wang X, Ying Y, Xie H, Yan H, et al. The dual role of N6-methyladenosine modification of RNAs is involved in human cancers. J Cell Mol Med. 2018;22(10):4630\u20139. https:\/\/doi.org\/10.1111\/jcmm.13804.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2072_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41422-018-0040-8","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m (6) a decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28(6):616\u201324. https:\/\/doi.org\/10.1038\/s41422-018-0040-8.","journal-title":"Cell Res"},{"key":"2072_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.sbi.2017.05.011","volume":"47","author":"B Wu","year":"2017","unstructured":"Wu B, Li L, Huang Y, Ma J, Min J. Readers, writers and erasers of N (6)-methylated adenosine modification. Curr Opin Struct Biol. 2017;47:67\u201376. https:\/\/doi.org\/10.1016\/j.sbi.2017.05.011.","journal-title":"Curr Opin Struct Biol"},{"key":"2072_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2020.01.021","volume":"474","author":"R Esteve-Puig","year":"2020","unstructured":"Esteve-Puig R, Bueno-Costa A, Esteller M. Writers, readers and erasers of RNA modifications in cancer. Cancer Lett. 2020;474:127\u201337. https:\/\/doi.org\/10.1016\/j.canlet.2020.01.021.","journal-title":"Cancer Lett"},{"key":"2072_CR8","doi-asserted-by":"crossref","unstructured":"Liu Z-X, Li L-M, Sun H-L, Liu S-M. Link Between m6A Modification and Cancers. Frontiers in Bioengineering and Biotechnology. 2018;6(89).","DOI":"10.3389\/fbioe.2018.00089"},{"key":"2072_CR9","doi-asserted-by":"crossref","unstructured":"Tzelepis K, De Braekeleer E, Yankova E, Rak J, Aspris D, Domingues AF, et al. Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia. Blood. 2019;134(Supplement_1):403.","DOI":"10.1182\/blood-2019-127962"},{"key":"2072_CR10","doi-asserted-by":"crossref","unstructured":"Lobo J, Costa AL, Cantante M, Guimaraes R, Lopes P, Antunes L, et al. m (6) A RNA modification and its writer\/reader VIRMA\/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance. J Transl Med. 2019;17(1):79.","DOI":"10.1186\/s12967-019-1837-z"},{"issue":"4","key":"2072_CR11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/andr.12612","volume":"7","author":"D Nettersheim","year":"2019","unstructured":"Nettersheim D, Berger D, Jostes S, Kristiansen G, Lochnit G, Schorle H. N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1\/F1\/F2, and HNRNPC as writers, erasers, and readers. Andrology. 2019;7(4):498\u2013506. https:\/\/doi.org\/10.1111\/andr.12612.","journal-title":"Andrology."},{"key":"2072_CR12","first-page":"963689720946653","volume":"29","author":"Y Luo","year":"2020","unstructured":"Luo Y, Sun Y, Li L, Mao Y. METTL3 may regulate testicular germ cell tumors through EMT and immune pathways. Cell Transplant. 2020;29:963689720946653.","journal-title":"Cell Transplant"},{"issue":"19","key":"2072_CR13","doi-asserted-by":"publisher","first-page":"11366","DOI":"10.1111\/jcmm.15738","volume":"24","author":"J Wei","year":"2020","unstructured":"Wei J, Yin Y, Zhou J, Chen H, Peng J, Yang J, et al. METTL3 potentiates resistance to cisplatin through m (6) a modification of TFAP2C in seminoma. J Cell Mol Med. 2020;24(19):11366\u201380. https:\/\/doi.org\/10.1111\/jcmm.15738.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2072_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.21037\/tau-20-963","volume":"10","author":"R Cong","year":"2021","unstructured":"Cong R, Ji C, Zhang J, Zhang Q, Zhou X, Yao L, et al. m6A RNA methylation regulators play an important role in the prognosis of patients with testicular germ cell tumor. Transl Androl Urol. 2021;10(2):662\u201379. https:\/\/doi.org\/10.21037\/tau-20-963.","journal-title":"Transl Androl Urol"},{"key":"2072_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.humpath.2018.07.016","volume":"82","author":"J Lobo","year":"2018","unstructured":"Lobo J, Costa AL, Vilela-Salgueiro B, Rodrigues A, Guimaraes R, Cantante M, et al. Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists. Hum Pathol. 2018;82:113\u201324. https:\/\/doi.org\/10.1016\/j.humpath.2018.07.016.","journal-title":"Hum Pathol"},{"issue":"9","key":"2072_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41568-019-0178-9","volume":"19","author":"JW Oosterhuis","year":"2019","unstructured":"Oosterhuis JW, Looijenga LHJ. Human germ cell tumours from a developmental perspective. Nat Rev Cancer. 2019;19(9):522\u201337. https:\/\/doi.org\/10.1038\/s41568-019-0178-9.","journal-title":"Nat Rev Cancer"},{"key":"2072_CR17","doi-asserted-by":"crossref","unstructured":"Lobo J, Gillis AJM, Jeronimo C, Henrique R, Looijenga LHJ. Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic. Int J Mol Sci. 2019;20(2):258.","DOI":"10.3390\/ijms20020258"},{"issue":"8","key":"2072_CR18","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1093\/nar\/gky130","volume":"46","author":"D Yang","year":"2018","unstructured":"Yang D, Qiao J, Wang G, Lan Y, Li G, Guo X, et al. N6-Methyladenosine modification of lincRNA 1281 is critically required for mESC differentiation potential. Nucleic Acids Res. 2018;46(8):3906\u201320. https:\/\/doi.org\/10.1093\/nar\/gky130.","journal-title":"Nucleic Acids Res"},{"issue":"7695","key":"2072_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nature25784","volume":"555","author":"A Bertero","year":"2018","unstructured":"Bertero A, Brown S, Madrigal P, Osnato A, Ortmann D, Yiangou L, et al. The SMAD2\/3 interactome reveals that TGFbeta controls m (6) a mRNA methylation in pluripotency. Nature. 2018;555(7695):256\u20139. https:\/\/doi.org\/10.1038\/nature25784.","journal-title":"Nature."},{"issue":"6225","key":"2072_CR20","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1126\/science.1261417","volume":"347","author":"S Geula","year":"2015","unstructured":"Geula S, Moshitch-Moshkovitz S, Dominissini D, Mansour AA, Kol N, Salmon-Divon M, et al. Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. Science. 2015;347(6225):1002\u20136. https:\/\/doi.org\/10.1126\/science.1261417.","journal-title":"Science."},{"issue":"2","key":"2072_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ncb2902","volume":"16","author":"Y Wang","year":"2014","unstructured":"Wang Y, Li Y, Toth JI, Petroski MD, Zhang Z, Zhao JC. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol. 2014;16(2):191\u20138. https:\/\/doi.org\/10.1038\/ncb2902.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2072_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12935-021-01868-1","volume":"21","author":"W Zhu","year":"2021","unstructured":"Zhu W, Wang JZ, Wei JF, Lu C. Role of m6A methyltransferase component VIRMA in multiple human cancers (review). Cancer Cell Int. 2021;21(1):172. https:\/\/doi.org\/10.1186\/s12935-021-01868-1.","journal-title":"Cancer Cell Int"},{"key":"2072_CR23","doi-asserted-by":"crossref","unstructured":"Lobo J, Gillis AJM, van den Berg A, Dorssers LCJ, Belge G, Dieckmann KP, et al. Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells. 2019;8(12):1637.","DOI":"10.3390\/cells8121637"},{"key":"2072_CR24","doi-asserted-by":"crossref","unstructured":"Lobo J, Cardoso AR, Miranda-Goncalves V, Looijenga LHJ, Lopez M, Arimondo PB, et al. Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest. Pharmaceutics. 2021;13(1):73.","DOI":"10.3390\/pharmaceutics13010073"},{"issue":"3","key":"2072_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41416-020-0891-x","volume":"123","author":"MA Skowron","year":"2020","unstructured":"Skowron MA, Vermeulen M, Winkelhausen A, Becker TK, Bremmer F, Petzsch P, et al. CDK4\/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms. Br J Cancer. 2020;123(3):378\u201391. https:\/\/doi.org\/10.1038\/s41416-020-0891-x.","journal-title":"Br J Cancer"},{"key":"2072_CR26","doi-asserted-by":"crossref","unstructured":"Lobo J, Guimaraes-Teixeira C, Barros-Silva D, Miranda-Goncalves V, Camilo V, Guimaraes R, et al. Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors. Cancers (Basel). 2020;12(10):2903.","DOI":"10.3390\/cancers12102903"},{"issue":"10","key":"2072_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw104","volume":"44","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Zeng P, Li YH, Zhang Z, Cui Q. SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res. 2016;44(10):e91. https:\/\/doi.org\/10.1093\/nar\/gkw104.","journal-title":"Nucleic Acids Res"},{"key":"2072_CR28","doi-asserted-by":"crossref","unstructured":"Lobo J, Rodrigues A, Guimaraes R, Cantante M, Lopes P, Mauricio J, et al. Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1\/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. Cancers (Basel). 2019;11(10):1535.","DOI":"10.3390\/cancers11101535"},{"key":"2072_CR29","doi-asserted-by":"crossref","unstructured":"Barros-Silva D, Lobo J, Guimaraes-Teixeira C, Carneiro I, Oliveira J, Martens-Uzunova ES, et al. VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer. Cancers (Basel). 2020;12(4):771.","DOI":"10.3390\/cancers12040771"},{"key":"2072_CR30","doi-asserted-by":"crossref","unstructured":"Lobo J, Jeronimo C, Henrique R. Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives. Cancers (Basel). 2020;12(6).","DOI":"10.3390\/cancers12061601"},{"issue":"1","key":"2072_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016174","volume":"6","author":"DE Coyle","year":"2011","unstructured":"Coyle DE, Li J, Baccei M. Regional differentiation of retinoic acid-induced human pluripotent embryonic carcinoma stem cell neurons. PLoS One. 2011;6(1):e16174. https:\/\/doi.org\/10.1371\/journal.pone.0016174.","journal-title":"PLoS One"},{"key":"2072_CR32","doi-asserted-by":"publisher","unstructured":"Batista PJ. The RNA Modification N (6)-methyladenosine and Its Implications in Human Disease. Genomics Proteomics Bioinformatics. 2017;15(3):154\u2013163, The RNA Modification N 6 -methyladenosine and Its Implications in Human Disease, DOI: https:\/\/doi.org\/10.1016\/j.gpb.2017.03.002.","DOI":"10.1016\/j.gpb.2017.03.002"},{"issue":"9","key":"2072_CR33","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/febs.13614","volume":"283","author":"A Maity","year":"2016","unstructured":"Maity A, Das B. N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases. FEBS J. 2016;283(9):1607\u201330. https:\/\/doi.org\/10.1111\/febs.13614.","journal-title":"FEBS J"},{"issue":"1","key":"2072_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6(1):74. https:\/\/doi.org\/10.1038\/s41392-020-00450-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2072_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1158\/2159-8290.CD-16-1292","volume":"7","author":"M Esteller","year":"2017","unstructured":"Esteller M, Pandolfi PP. The Epitranscriptome of noncoding RNAs in Cancer. Cancer Discov. 2017;7(4):359\u201368. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1292.","journal-title":"Cancer Discov"},{"issue":"1","key":"2072_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-cellbio-100616-060758","volume":"33","author":"KD Meyer","year":"2017","unstructured":"Meyer KD, Jaffrey SR. Rethinking m (6) a readers, writers, and erasers. Annu Rev Cell Dev Biol. 2017;33(1):319\u201342. https:\/\/doi.org\/10.1146\/annurev-cellbio-100616-060758.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2072_CR37","doi-asserted-by":"crossref","unstructured":"Schaefer M, Kapoor U, Jantsch MF. Understanding RNA modifications: the promises and technological bottlenecks of the 'epitranscriptome'. Open Biol. 2017;7(5):170077.","DOI":"10.1098\/rsob.170077"},{"issue":"3","key":"2072_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.gpb.2017.03.003","volume":"15","author":"X Xiong","year":"2017","unstructured":"Xiong X, Yi C, Peng J. Epitranscriptomics: toward a better understanding of RNA modifications. Genomics Proteomics Bioinformatics. 2017;15(3):147\u201353. https:\/\/doi.org\/10.1016\/j.gpb.2017.03.003.","journal-title":"Genomics Proteomics Bioinformatics."},{"issue":"5","key":"2072_CR39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-018-0034-6","volume":"28","author":"X Deng","year":"2018","unstructured":"Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N (6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28(5):507\u201317. https:\/\/doi.org\/10.1038\/s41422-018-0034-6.","journal-title":"Cell Res"},{"issue":"5","key":"2072_CR40","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/s12276-020-0432-y","volume":"52","author":"SH Han","year":"2020","unstructured":"Han SH, Choe J. Diverse molecular functions of m (6) a mRNA modification in cancer. Exp Mol Med. 2020;52(5):738\u201349. https:\/\/doi.org\/10.1038\/s12276-020-0432-y.","journal-title":"Exp Mol Med"},{"key":"2072_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fbioe.2018.00089","volume":"6","author":"ZX Liu","year":"2018","unstructured":"Liu ZX, Li LM, Sun HL, Liu SM. Link between m6A modification and cancers. Front Bioeng Biotechnol. 2018;6:89. https:\/\/doi.org\/10.3389\/fbioe.2018.00089.","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"2072_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.trecan.2018.01.006","volume":"4","author":"H Lian","year":"2018","unstructured":"Lian H, Wang QH, Zhu CB, Ma J, Jin WL. Deciphering the Epitranscriptome in Cancer. Trends Cancer. 2018;4(3):207\u201321. https:\/\/doi.org\/10.1016\/j.trecan.2018.01.006.","journal-title":"Trends Cancer"},{"issue":"2","key":"2072_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5483\/BMBRep.2021.54.2.212","volume":"54","author":"SH Han","year":"2021","unstructured":"Han SH, Choe J. Deciphering the molecular mechanisms of epitranscriptome regulation in cancer. BMB Rep. 2021;54(2):89\u201397. https:\/\/doi.org\/10.5483\/BMBRep.2021.54.2.212.","journal-title":"BMB Rep"},{"key":"2072_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2017.08.030","volume":"408","author":"S Wang","year":"2017","unstructured":"Wang S, Sun C, Li J, Zhang E, Ma Z, Xu W, et al. Roles of RNA methylation by means of N (6)-methyladenosine (m (6) a) in human cancers. Cancer Lett. 2017;408:112\u201320. https:\/\/doi.org\/10.1016\/j.canlet.2017.08.030.","journal-title":"Cancer Lett"},{"issue":"5","key":"2072_CR45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41590-020-0650-4","volume":"21","author":"Z Shulman","year":"2020","unstructured":"Shulman Z, Stern-Ginossar N. The RNA modification N (6)-methyladenosine as a novel regulator of the immune system. Nat Immunol. 2020;21(5):501\u201312. https:\/\/doi.org\/10.1038\/s41590-020-0650-4.","journal-title":"Nat Immunol"},{"issue":"4","key":"2072_CR46","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s12015-019-09894-3","volume":"15","author":"V Haran","year":"2019","unstructured":"Haran V, Lenka N. Deciphering the Epitranscriptomic signatures in cell fate determination and development. Stem Cell Rev Rep. 2019;15(4):474\u201396. https:\/\/doi.org\/10.1007\/s12015-019-09894-3.","journal-title":"Stem Cell Rev Rep"},{"issue":"6","key":"2072_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.stem.2014.09.019","volume":"15","author":"PJ Batista","year":"2014","unstructured":"Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, et al. M (6) a RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014;15(6):707\u201319. https:\/\/doi.org\/10.1016\/j.stem.2014.09.019.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2072_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41593-017-0057-1","volume":"21","author":"Y Wang","year":"2018","unstructured":"Wang Y, Li Y, Yue M, Wang J, Kumar S, Wechsler-Reya RJ, et al. N (6)-methyladenosine RNA modification regulates embryonic neural stem cell self-renewal through histone modifications. Nat Neurosci. 2018;21(2):195\u2013206. https:\/\/doi.org\/10.1038\/s41593-017-0057-1.","journal-title":"Nat Neurosci"},{"issue":"6","key":"2072_CR49","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.molcel.2018.02.015","volume":"69","author":"J Wen","year":"2018","unstructured":"Wen J, Lv R, Ma H, Shen H, He C, Wang J, et al. Zc3h13 regulates nuclear RNA m (6) a methylation and mouse embryonic stem cell self-renewal. Mol Cell. 2018;69(6):1028\u201338 e6. https:\/\/doi.org\/10.1016\/j.molcel.2018.02.015.","journal-title":"Mol Cell"},{"issue":"2","key":"2072_CR50","doi-asserted-by":"publisher","first-page":"E325","DOI":"10.1073\/pnas.1717794115","volume":"115","author":"C Tang","year":"2018","unstructured":"Tang C, Klukovich R, Peng H, Wang Z, Yu T, Zhang Y, et al. ALKBH5-dependent m6A demethylation controls splicing and stability of long 3\u2032-UTR mRNAs in male germ cells. Proc Natl Acad Sci U S A. 2018;115(2):E325\u2013E33. https:\/\/doi.org\/10.1073\/pnas.1717794115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2072_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41698-019-0085-2","volume":"3","author":"R Kandimalla","year":"2019","unstructured":"Kandimalla R, Gao F, Li Y, Huang H, Ke J, Deng X, et al. RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. NPJ Precis Oncol. 2019;3(1):13. https:\/\/doi.org\/10.1038\/s41698-019-0085-2.","journal-title":"NPJ Precis Oncol"},{"key":"2072_CR52","doi-asserted-by":"publisher","first-page":"112325","DOI":"10.1016\/j.ejmech.2020.112325","volume":"196","author":"J Gu","year":"2020","unstructured":"Gu J, Xu J, You Q, Guo X. Recent developments of small molecules targeting RNA m (6) a modulators. Eur J Med Chem. 2020;196:112325. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112325.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"2072_CR53","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105977","volume":"40","author":"PC He","year":"2021","unstructured":"He PC, He C. m6A RNA methylation: from mechanisms to therapeutic potential. EMBO J. 2021;40(3):e105977. https:\/\/doi.org\/10.15252\/embj.2020105977.","journal-title":"EMBO J"},{"issue":"4","key":"2072_CR54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41585-020-0296-x","volume":"17","author":"K Almstrup","year":"2020","unstructured":"Almstrup K, Lobo J, Morup N, Belge G, Rajpert-De Meyts E, Looijenga LHJ, et al. Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat Rev Urol. 2020;17(4):201\u201313. https:\/\/doi.org\/10.1038\/s41585-020-0296-x.","journal-title":"Nat Rev Urol"},{"issue":"4 Pt 2","key":"2072_CR55","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1111\/j.1365-2605.2011.01148.x","volume":"34","author":"AJ Gillis","year":"2011","unstructured":"Gillis AJ, Stoop H, Biermann K, van Gurp RJ, Swartzman E, Cribbes S, et al. Expression and interdependencies of pluripotency factors LIN28, OCT3\/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis. Int J Androl. 2011;34(4 Pt 2):e160\u201374. https:\/\/doi.org\/10.1111\/j.1365-2605.2011.01148.x.","journal-title":"Int J Androl"},{"issue":"33","key":"2072_CR56","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.1038\/s41388-019-0861-z","volume":"38","author":"JY Qian","year":"2019","unstructured":"Qian JY, Gao J, Sun X, Cao MD, Shi L, Xia TS, et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene. 2019;38(33):6123\u201341. https:\/\/doi.org\/10.1038\/s41388-019-0861-z.","journal-title":"Oncogene."},{"key":"2072_CR57","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.2147\/OTT.S180954","volume":"12","author":"X Cheng","year":"2019","unstructured":"Cheng X, Li M, Rao X, Zhang W, Li X, Wang L, et al. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA. Onco Targets Ther. 2019;12:3421\u20138. https:\/\/doi.org\/10.2147\/OTT.S180954.","journal-title":"Onco Targets Ther."},{"issue":"10","key":"2072_CR58","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.1002\/jcp.29645","volume":"235","author":"R Miao","year":"2020","unstructured":"Miao R, Dai CC, Mei L, Xu J, Sun SW, Xing YL, et al. KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in gastric cancer. J Cell Physiol. 2020;235(10):7420\u201332. https:\/\/doi.org\/10.1002\/jcp.29645.","journal-title":"J Cell Physiol"},{"issue":"1","key":"2072_CR59","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12943-019-1106-z","volume":"18","author":"T Lan","year":"2019","unstructured":"Lan T, Li H, Zhang D, Xu L, Liu H, Hao X, et al. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019;18(1):186. https:\/\/doi.org\/10.1186\/s12943-019-1106-z.","journal-title":"Mol Cancer"},{"key":"2072_CR60","doi-asserted-by":"publisher","first-page":"153284","DOI":"10.1016\/j.prp.2020.153284","volume":"217","author":"W Zhao","year":"2021","unstructured":"Zhao W, Xie Y. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A. Pathol Res Pract. 2021;217:153284. https:\/\/doi.org\/10.1016\/j.prp.2020.153284.","journal-title":"Pathol Res Pract"},{"issue":"12","key":"2072_CR61","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41419-020-03279-y","volume":"11","author":"C Macedo-Silva","year":"2020","unstructured":"Macedo-Silva C, Miranda-Goncalves V, Lameirinhas A, Lencart J, Pereira A, Lobo J, et al. JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. Cell Death Dis. 2020;11(12):1068. https:\/\/doi.org\/10.1038\/s41419-020-03279-y.","journal-title":"Cell Death Dis"},{"issue":"12","key":"2072_CR62","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/1878-0261.12582","volume":"13","author":"G Steinemann","year":"2019","unstructured":"Steinemann G, Dittmer A, Schmidt J, Josuttis D, Fahling M, Biersack B, et al. Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer. Mol Oncol. 2019;13(12):2679\u201396. https:\/\/doi.org\/10.1002\/1878-0261.12582.","journal-title":"Mol Oncol"},{"issue":"1","key":"2072_CR63","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12935-020-01458-7","volume":"20","author":"S Schmidtova","year":"2020","unstructured":"Schmidtova S, Dorssers LCJ, Kalavska K, Gillis AJM, Oosterhuis JW, Stoop H, et al. Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness. Cancer Cell Int. 2020;20(1):364. https:\/\/doi.org\/10.1186\/s12935-020-01458-7.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"2072_CR64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ymthe.2019.11.016","volume":"28","author":"X Chen","year":"2020","unstructured":"Chen X, Xu M, Xu X, Zeng K, Liu X, Sun L, et al. METTL14 suppresses CRC progression via regulating N6-Methyladenosine-dependent primary miR-375 processing. Mol Ther. 2020;28(2):599\u2013612. https:\/\/doi.org\/10.1016\/j.ymthe.2019.11.016.","journal-title":"Mol Ther"},{"key":"2072_CR65","doi-asserted-by":"crossref","unstructured":"Yan G, Yuan Y, He M, Gong R, Lei H, Zhou H, et al. m (6) A Methylation of Precursor-miR-320\/RUNX2 Controls Osteogenic Potential of Bone Marrow-Derived Mesenchymal Stem Cells. Mol Ther Nucleic Acids. 2020;19:421\u201336.","DOI":"10.1016\/j.omtn.2019.12.001"},{"key":"2072_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2020.01.033","volume":"20","author":"W Zhao","year":"2020","unstructured":"Zhao W, Cui Y, Liu L, Ma X, Qi X, Wang Y, et al. METTL3 facilitates Oral squamous cell carcinoma tumorigenesis by enhancing c-Myc stability via YTHDF1-mediated m (6) a modification. Mol Ther Nucleic Acids. 2020;20:1\u201312. https:\/\/doi.org\/10.1016\/j.omtn.2020.01.033.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"2072_CR67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.gpb.2018.03.001","volume":"16","author":"J Huang","year":"2018","unstructured":"Huang J, Yin P. Structural insights into N (6)-methyladenosine (m (6) a) modification in the transcriptome. Genomics Proteomics Bioinformatics. 2018;16(2):85\u201398. https:\/\/doi.org\/10.1016\/j.gpb.2018.03.001.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"9","key":"2072_CR68","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2217\/epi-2019-0358","volume":"12","author":"M Xiang","year":"2020","unstructured":"Xiang M, Liu W, Tian W, You A, Deng D. RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy. Epigenomics. 2020;12(9):801\u20139. https:\/\/doi.org\/10.2217\/epi-2019-0358.","journal-title":"Epigenomics."},{"issue":"1","key":"2072_CR69","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/andr.299","volume":"3","author":"C Jacobsen","year":"2015","unstructured":"Jacobsen C, Honecker F. Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology. 2015;3(1):111\u201321. https:\/\/doi.org\/10.1111\/andr.299.","journal-title":"Andrology."},{"issue":"8","key":"2072_CR70","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00345-016-1898-z","volume":"35","author":"C Oing","year":"2017","unstructured":"Oing C, Alsdorf WH, von Amsberg G, Oechsle K, Bokemeyer C. Platinum-refractory germ cell tumors: an update on current treatment options and developments. World J Urol. 2017;35(8):1167\u201375. https:\/\/doi.org\/10.1007\/s00345-016-1898-z.","journal-title":"World J Urol"},{"issue":"4","key":"2072_CR71","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/andr.12611","volume":"7","author":"C Oing","year":"2019","unstructured":"Oing C, Skowron MA, Bokemeyer C, Nettersheim D. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations. Andrology. 2019;7(4):487\u201397. https:\/\/doi.org\/10.1111\/andr.12611.","journal-title":"Andrology."},{"key":"2072_CR72","doi-asserted-by":"crossref","unstructured":"Cardoso AR, Lobo J, Miranda-Goncalves V, Henrique R, Jeronimo C. Epigenetic alterations as therapeutic targets in testicular germ cell Tumours : current and future application of 'epidrugs'. Epigenetics. 2020:1\u201320.","DOI":"10.1080\/15592294.2020.1805682"},{"key":"2072_CR73","doi-asserted-by":"crossref","unstructured":"Sishc BJ, Davis AJ. The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer. Cancers (Basel). 2017;9(7):81.","DOI":"10.3390\/cancers9070081"},{"issue":"7","key":"2072_CR74","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/abbs\/gmw046","volume":"48","author":"K Yang","year":"2016","unstructured":"Yang K, Guo R, Xu D. Non-homologous end joining: advances and frontiers. Acta Biochim Biophys Sin Shanghai. 2016;48(7):632\u201340. https:\/\/doi.org\/10.1093\/abbs\/gmw046.","journal-title":"Acta Biochim Biophys Sin Shanghai"},{"key":"2072_CR75","doi-asserted-by":"publisher","first-page":"10139","DOI":"10.2147\/OTT.S221025","volume":"12","author":"T Zhang","year":"2019","unstructured":"Zhang T, Chai J, Chi L. Induction of XLF and 53BP1 expression is associated with Temozolomide resistance in glioblastoma cells. Onco Targets Ther. 2019;12:10139\u201351. https:\/\/doi.org\/10.2147\/OTT.S221025.","journal-title":"Onco Targets Ther"},{"issue":"11","key":"2072_CR76","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1111\/1759-7714.13142","volume":"11","author":"T Zhou","year":"2020","unstructured":"Zhou T, Fu H, Dong B, Dai L, Yang Y, Yan W, et al. HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair. Thorac Cancer. 2020;11(11):3071\u201385. https:\/\/doi.org\/10.1111\/1759-7714.13142.","journal-title":"Thorac Cancer"},{"issue":"11","key":"2072_CR77","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1593\/neo.111032","volume":"13","author":"EA Stronach","year":"2011","unstructured":"Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, et al. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia. 2011;13(11):1069\u201380. https:\/\/doi.org\/10.1593\/neo.111032.","journal-title":"Neoplasia."},{"issue":"1","key":"2072_CR78","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12885-017-3345-y","volume":"17","author":"S Yang","year":"2017","unstructured":"Yang S, Wang XQ. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance. BMC Cancer. 2017;17(1):344. https:\/\/doi.org\/10.1186\/s12885-017-3345-y.","journal-title":"BMC Cancer"},{"issue":"42","key":"2072_CR79","doi-asserted-by":"publisher","first-page":"68662","DOI":"10.18632\/oncotarget.11900","volume":"7","author":"P Domagala","year":"2016","unstructured":"Domagala P, Hybiak J, Rys J, Byrski T, Cybulski C, Lubinski J. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers. Oncotarget. 2016;7(42):68662\u201373. https:\/\/doi.org\/10.18632\/oncotarget.11900.","journal-title":"Oncotarget."},{"key":"2072_CR80","doi-asserted-by":"crossref","unstructured":"Caggiano C, Cavallo F, Giannattasio T, Cappelletti G, Rossi P, Grimaldi P, et al. Testicular Germ Cell Tumors Acquire Cisplatin Resistance by Rebalancing the Usage of DNA Repair Pathways. Cancers (Basel). 2021;13(4):787.","DOI":"10.3390\/cancers13040787"},{"issue":"6","key":"2072_CR81","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrd.2018.71","volume":"17","author":"PA Boriack-Sjodin","year":"2018","unstructured":"Boriack-Sjodin PA, Ribich S, Copeland RA. RNA-modifying proteins as anticancer drug targets. Nat Rev Drug Discov. 2018;17(6):435\u201353. https:\/\/doi.org\/10.1038\/nrd.2018.71.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2072_CR82","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.apsb.2018.06.001","volume":"8","author":"Y Niu","year":"2018","unstructured":"Niu Y, Wan A, Lin Z, Lu X, Wan G. N (6)-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development. Acta Pharm Sin B. 2018;8(6):833\u201343. https:\/\/doi.org\/10.1016\/j.apsb.2018.06.001.","journal-title":"Acta Pharm Sin B"},{"issue":"7860","key":"2072_CR83","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597\u2013601. https:\/\/doi.org\/10.1038\/s41586-021-03536-w.","journal-title":"Nature."},{"issue":"4","key":"2072_CR84","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/cjoc.201900490","volume":"38","author":"G-Q Lai","year":"2020","unstructured":"Lai G-Q, Zhou L-L, Yang C-G. RNA methylation m6A: a new code and drug target? Chin J Chem. 2020;38(4):420\u20131. https:\/\/doi.org\/10.1002\/cjoc.201900490.","journal-title":"Chin J Chem"},{"issue":"2","key":"2072_CR85","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.biochem.9b00755","volume":"59","author":"LL Zhou","year":"2020","unstructured":"Zhou LL, Yang CG. Targeting Epitranscriptomic proteins for therapeutic intervention. Biochemistry. 2020;59(2):125\u20137. https:\/\/doi.org\/10.1021\/acs.biochem.9b00755.","journal-title":"Biochemistry."},{"key":"2072_CR86","doi-asserted-by":"crossref","unstructured":"Lobo J, Constancio V, Guimaraes-Teixeira C, Leite-Silva P, Miranda-Goncalves V, Sequeira JP, et al. Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Mol Oncol. 2021;15(4):846\u201365.","DOI":"10.1002\/1878-0261.12909"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02072-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-02072-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02072-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T08:03:27Z","timestamp":1629965007000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-02072-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2072"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-02072-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee (CES-IPO-1\/018) of Portuguese Oncology Institute of Porto, Portugal. All procedures performed in tasks involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}